Literature DB >> 9751465

Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link?

G Husby1, P Blichfeldt, L Brinch, P Brandtzaeg, O J Mellbye, K Sletten, T Stenstad.   

Abstract

In 1991, gamma heavy chain disease was diagnosed in a 43-year-old female, who 3 years earlier had contracted an erosive seronegative chronic arthropathy. Her gamma heavy chain disease had a benign course, requiring no specific therapy for 5 years. In 1996, however, her lymphoproliferative disorder underwent a more malignant course, with renal and cardiac failure and increasing articular problems, requiring treatment with melphalan and prednisolone, following the protocol for myelomatosis. Laboratory studies revealed a monoclonal component in serum and urine. consistent with dimers of gamma-chains of the gamma3 subclass, but with a smaller molecular mass than normal gamma3-chains, suggesting molecular aberrations as consistently observed in this disorder. Massive localization of plasma cells and blasts with cytoplasmic or cell membrane staining for gamma3-chains, but no staining for kappa or lambda light chains, was observed by immunohistochemical studies of tissue specimens from bone marrow as well as affected synovial tissue. Large amounts of extracellular gamma3-chains were deposited in the synovial membrane. In addition, marked inflammatory changes with synovial cell hyperplasia were seen. Whether the present case represents primarily a gamma heavy chain deposition disease with reactive inflammatory changes in the joints, or another example of gamma heavy chain disease preceded by seronegative rheumatoid arthritis, remains elusive. Regardless, a possible pathogenic link between the two disease processes is an intriguing possibility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751465

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  6 in total

1.  Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases.

Authors:  Shannon Bieliauskas; Raymond R Tubbs; Chris M Bacon; Camellia Eshoa; Kathryn Foucar; Sarah E Gibson; Steven H Kroft; Aliyah R Sohani; Steven H Swerdlow; James R Cook
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Gamma 1-heavy chain deposition disease accompanied by IgG kappa in serum, urine, and bone marrow.

Authors:  Keiichi Kaneko; Koichi Seta; Jun Soma; Takashi Kuwahara; Mitsuteru Koizumi; Yuko Kikuchi; Akira Sugawara; Kensei Yahata
Journal:  CEN Case Rep       Date:  2013-07-10

3.  Heavy-chain deposition disease: a morphological, immunofluorescence and ultrastructural assessment.

Authors:  Swapnil Rane; Seema Rana; Chetan Mudrabettu; Vivekananda Jha; Kusum Joshi
Journal:  Clin Kidney J       Date:  2012-10

4.  Gamma-heavy chain monoclonal gammopathy with undetermined significance (MGUS).

Authors:  Yuriko Zushi; Miho Sasaki; Toshiharu Saitoh; Yumi Aoyama; Yuta Gotoh; Hiroko Tsunemine; Taiichi Kodaka; Atsuo Okamura; Takayuki Takahashi
Journal:  J Clin Exp Hematop       Date:  2019-08-08

5.  Gamma heavy chain disease associated with rheumatoid arthritis: a case report.

Authors:  Gwenvaël Danic; Thomas Dejoie; Hélène Caillon; Aurélie Achille; Pierre Pottier; Christian Agard
Journal:  J Med Case Rep       Date:  2021-03-17

6.  Gamma heavy chain disease (γ-HCD) as iatrogenic immunodeficiency- associated lymphoproliferative disorder: Possible emergent subtype of rheumatoid arthritis-associated γ-HCD.

Authors:  Hiroko Tsunemine; Yuriko Zushi; Miho Sasaki; Yuko Nishikawa; Akiyo Tamura; Yumi Aoyama; Taiichi Kodaka; Tomoo Itoh; Takayuki Takahashi
Journal:  J Clin Exp Hematop       Date:  2019
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.